An open‐label, phase 1, randomized, three treatments, three‐period, crossover, relative bioavailability study of CC‐292, a potent and orally available inhibitor of bruton tyrosine kinase
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacy and Therapeutics"
DOI: 10.1111/jcpt.13653
Abstract: CC‐292 is a potent, selective, orally administered small molecule inhibitor of bruton tyrosine kinase (BTK). The aim of this study was to evaluate the relative bioavailability of newly developed CC‐292 tablet formulation (P22 tablet (P22‐TAB)… read more here.
Keywords: 292 potent; bruton tyrosine; relative bioavailability; inhibitor bruton ... See more keywords